

# Arnaud Bruyere

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7735348/publications.pdf>

Version: 2024-02-01

26  
papers

451  
citations

623188

14  
h-index

713013

21  
g-index

26  
all docs

26  
docs citations

26  
times ranked

507  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass. <i>Molecular Pharmaceutics</i> , 2010, 7, 1596-1607.	2.3	84
2	Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. <i>PLoS ONE</i> , 2017, 12, e0169480.	1.1	33
3	Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains. <i>Xenobiotica</i> , 2009, 39, 22-32.	0.5	32
4	The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2018, 46, 131-140.	1.7	30
5	Generation of proliferating human adult hepatocytes using optimized 3D culture conditions. <i>Scientific Reports</i> , 2021, 11, 515.	1.6	29
6	Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. <i>Xenobiotica</i> , 2019, 49, 363-374.	0.5	25
7	Interactions of pesticides with membrane drug transporters: implications for toxicokinetics and toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 739-752.	1.5	23
8	In Silico Prediction for Intestinal Absorption and Brain Penetration of Chemical Pesticides in Humans. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 708.	1.2	22
9	Interactions of Endosulfan and Methoxychlor Involving CYP3A4 and CYP2B6 in Human HepaRG Cells. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1235-1240.	1.7	21
10	Functional polarization of human hepatoma HepaRG cells in response to forskolin. <i>Scientific Reports</i> , 2018, 8, 16115.	1.6	16
11	Implication of human drug transporters to toxicokinetics and toxicity of pesticides. <i>Pest Management Science</i> , 2020, 76, 18-25.	1.7	16
12	Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 259-271.	1.5	16
13	Inhibition of SLC drug transporter activities by environmental bisphenols. <i>Toxicology in Vitro</i> , 2017, 40, 34-44.	1.1	15
14	DMSO-free highly differentiated HepaRG spheroids for chronic toxicity, liver functions and genotoxicity studies. <i>Archives of Toxicology</i> , 2022, 96, 243-258.	1.9	15
15	Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220. <i>PLoS ONE</i> , 2015, 10, e0144667.	1.1	11
16	Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. <i>Toxicology in Vitro</i> , 2019, 54, 10-22.	1.1	10
17	Differential interactions of carbamate pesticides with drug transporters. <i>Xenobiotica</i> , 2020, 50, 1380-1392.	0.5	10
18	Inhibition of organic cation transporter 3 activity by tyrosine kinase inhibitors. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 919-929.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Neonicotinoid pesticides poorly interact with human drug transporters. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22379.	1.4	8
20	Comparative in silico prediction of P-glycoprotein-mediated transport for 2010-2020 US FDA-approved drugs using six Web tools. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 393-398.	1.1	8
21	Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells. <i>International Immunopharmacology</i> , 2020, 83, 106439.	1.7	5
22	PBPK model of methotrexate in cerebrospinal fluid ventricles using a combined microdialysis and MRI acquisition. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 104, 117-130.	2.0	4
23	Differential <i>in vitro</i> interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters. <i>Xenobiotica</i> , 2021, 51, 467-478.	0.5	3
24	Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 625-635.	0.6	3
25	Substrate-Dependent Trans-Stimulation of Organic Cation Transporter 2 Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12926.	1.8	2
26	Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 164, 36-53.	2.0	1